CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: EZLibra who wrote (97)	8/9/1998 3:03:00 PM
From: scaram(o)uche	Read Replies (2) of 666

Davis: Man, this guy can write. Very thoughtful, ultimately useful. >> I agree with Winn completely that I would rather take on 10,000 cells with multiple antibodies than wait for the emergence of 100 million cells months later that have changed on me << OK, so companies with "strong currencies" (those that are selling at a nice multiple to book, the IMNXs or IDPHs or GNEs of the world) should be out doing diligent research on TCLN and considering an acquisition, no? V1, your thoughts?? >> and BobLLL is quite correct and articulate about the dependence of cell-type and affinity and expression of binding sites on varying types of lymphoma, especially since low-grade is primarily a B-cell phenotype << Can you expand on what is meant here? Not on the basics, as my background is serology of the lymphocyte cell surface. Specifics.... what are the situations that oncolym addresses that the anti-CD20s don't? If this has already been addressed repeatedly and you can point to some posts, please excuse me for asking. It's been awhile since I looked at TCLN. Stone is gone now, correct? Who did they get to replace him? Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next